On January 28, 2016, the U. S. Food and Drug Administration approved eribulin (HALAVEN injection, Eisai Co., Ltd.) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
Are you looking for or in search of FDA approved “Eribulin mesylate Injection in India”? “Medicant Healthcare” a registered pharmacy firm in India deals in both brand name as well as generic name Drugs / medicine approved for unresectable or metastatic liposarcoma. Need Access of Eribulin mesylate Injection, get in touch with our healthcare professional.
HALAVEN is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting .
DOSAGE FORMS AND STRENGTHS
Eribulin mesylate injection, 1 mg per 2 mL (0.5 mg per mL).